Histopathologic study of eyes after iodine I 125 episcleral plaque irradiation for uveal melanoma.
OBJECTIVE
To describe the histopathologic findings attributable to irradiation in eyes with uveal malignant melanoma treated with iodine I 125 brachytherapy and to compare these findings with those reviewed in a previous study that compared histopathologic findings in eyes enucleated after proton beam teletherapy with those seen in eyes in a nonirradiated control group.


METHODS
The slides from 22 eyes with uveal melanoma that had undergone enucleation after the administration of 125I brachytherapy were studied. The histopathologic features of the tumor and the retina were graded. Results were compared with findings from a previously reported group of 47 proton beam-treated eyes and its control group.


RESULTS
Patient age, time between irradiation and enucleation, and ciliary body involvement were similar for the 125I brachytherapy-treated group and the proton beam-treated group and its control group. This allows comparison of the histopathologic findings. Comparing the 125I brachytherapy- and proton beam-treated groups, most histopathologic features were similar with nominally statistically significant differences only for cell type, number of mitotic figures, and fibrous metaplasia of the retinal pigment epithelium adjacent to the tumor.


CONCLUSIONS
Irradiation of uveal melanoma induces changes in the tumor and in the surrounding retina. Brachytherapy and charged particle therapy are the 2 principal methods of irradiation. This study demonstrates that similar changes are produced by 125I plaque irradiation and proton beam irradiation.
Saornil
M A
MA
Department of Ophthalmology, Universidad de Valladolid, Spain.
Fisher
M R
MR
Campbell
R J
RJ
Robertson
D M
DM
Earle
J D
JD
Eagle
R C
RC
Shields
J A
JA
Shields
C L
CL
Chandra
S R
SR
Albert
D M
DM
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000009:adverse effects; D015353:Eye Enucleation; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D008545:Melanoma / Q000473:pathology* / Q000532:radiotherapy; D008875:Middle Aged; D011832:Radiation Injuries / Q000209:etiology / Q000473:pathology*; D011882:Radiotherapy, High-Energy / Q000009:adverse effects; D012160:Retina / Q000473:pathology* / Q000528:radiation effects; D012590:Sclera; D014604:Uveal Neoplasms / Q000473:pathology* / Q000532:radiotherapy
D007457:Iodine Radioisotopes